• Executive Summary
o Market Overview
• Market Landscape
o Market ecosystem
o Value chain analysis
• Market Sizing
o Market definition
o Market segment analysis
o Market size 2019
o Market outlook: Forecast for 2019 – 2024
• Five Forces Analysis
o Five forces summary
o Bargaining power of buyers
o Bargaining power of suppliers
o Threat of new entrants
o Threat of substitutes
o Threat of rivalry
o Market condition
• Market Segmentation by route of administration
o Market segments
o Comparison by route of administration
o Oral – Market size and forecast 2019-2024
o Parenteral – Market size and forecast 2019-2024
o Market opportunity by route of administration
• Market Segmentation by class of drugs
o Peripherally acting mu-opioid receptor antagonists
o Locally acting chloride channel activator
o Other drugs
• Customer landscape
o Overview
• Geographic Landscape
o Geographic segmentation
o Geographic comparison
o North America – Market size and forecast 2019-2024
o Europe – Market size and forecast 2019-2024
o Asia – Market size and forecast 2019-2024
o ROW – Market size and forecast 2019-2024
o Key leading countries
o Market opportunity by geography
o Market drivers
o Market challenges
o Market trends
• Vendor Landscape
o Overview
o Landscape disruption
• Vendor Analysis
o Vendors covered
o Market positioning of vendors
o AstraZeneca Plc
o Bausch Health Companies Inc.
o Daiichi Sankyo Co. Ltd.
o Ironwood Pharmaceuticals Inc.
o Mallinckrodt Plc
o Merck & Co. Inc.
o Novartis AG
o Pfizer Inc.
o SHIONOGI Co. Ltd.
o Takeda Pharmaceutical Co. Ltd.
• Appendix
o Scope of the report
o Currency conversion rates for US$
o Research methodology
o List of abbreviations
Exhibit
• 1: Key Finding 1
• 2: Key Finding 2
• 3: Key Finding 3
• 4: Key Finding 5
• 5: Key Finding 6
• 6: Key Finding 7
• 7: Key Finding 8
• 8: Key Finding 9
• 9: Parent market
• 10: Market characteristics
• 11: Offerings of vendors included in the market definition
• 12: Market segments
• 13: Global – Market size and forecast 2019 – 2024 ($ million)
• 14: Global market: Year-over-year growth 2019 – 2024 (%)
• 15: Five forces analysis 2019 & 2024
• 16: Bargaining power of buyers
• 17: Bargaining power of suppliers
• 18: Threat of new entrants
• 19: Threat of substitutes
• 20: Threat of rivalry
• 21: Market condition – Five forces 2019
• 22: Other1 – Market share 2019-2024 (%)
• 23: Comparison by Other1
• 24: Oral – Market size and forecast 2019-2024 ($ million)
• 25: Oral – Year-over-year growth 2019-2024 (%)
• 26: Parenteral – Market size and forecast 2019-2024 ($ million)
• 27: Parenteral – Year-over-year growth 2019-2024 (%)
• 28: Market opportunity by Other1
• 29: Other2 – Market share 2019-2024 (%)
• 30: Comparison by Other2
• 31: Peripherally acting mu-opioid receptor antagonists – Market size and forecast 2019-2024 ($ million)
• 32: Peripherally acting mu-opioid receptor antagonists – Year-over-year growth 2019-2024 (%)
• 33: Locally acting chloride channel activator – Market size and forecast 2019-2024 ($ million)
• 34: Locally acting chloride channel activator – Year-over-year growth 2019-2024 (%)
• 35: Others – Market size and forecast 2019-2024 ($ million)
• 36: Others – Year-over-year growth 2019-2024 (%)
• 37: Market opportunity by Other2
• 38: Customer landscape
• 39: Market share by geography 2019-2024 (%)
• 40: Geographic comparison
• 41: North America – Market size and forecast 2019-2024 ($ million)
• 42: North America – Year-over-year growth 2019-2024 (%)
• 43: Europe – Market size and forecast 2019-2024 ($ million)
• 44: Europe – Year-over-year growth 2019-2024 (%)
• 45: Asia – Market size and forecast 2019-2024 ($ million)
• 46: Asia – Year-over-year growth 2019-2024 (%)
• 47: ROW – Market size and forecast 2019-2024 ($ million)
• 48: ROW – Year-over-year growth 2019-2024 (%)
• 49: Key leading countries
• 50: Market opportunity by geography ($ million)
• 51: Impact of drivers and challenges
• 52: Vendor landscape
• 53: Landscape disruption
• 54: Industry risks
• 55: Vendors covered
• 56: Market positioning of vendors
• 57: AstraZeneca Plc – Overview
• 58: AstraZeneca Plc – Product and service
• 59: AstraZeneca Plc – Key offerings
• 60: AstraZeneca Plc – Key customers
• 61: AstraZeneca Plc – Segment focus
• 62: Bausch Health Companies Inc. – Overview
• 63: Bausch Health Companies Inc. – Business segments
• 64: Bausch Health Companies Inc. – Key offerings
• 65: Bausch Health Companies Inc. – Key customers
• 66: Bausch Health Companies Inc. – Segment focus
• 67: Daiichi Sankyo Co. Ltd. – Overview
• 68: Daiichi Sankyo Co. Ltd. – Business segments
• 69: Daiichi Sankyo Co. Ltd. – Key offerings
• 70: Daiichi Sankyo Co. Ltd. – Key customers
• 71: Daiichi Sankyo Co. Ltd. – Segment focus
• 72: Ironwood Pharmaceuticals Inc. – Overview
• 73: Ironwood Pharmaceuticals Inc. – Business segments
• 74: Ironwood Pharmaceuticals Inc. – Key offerings
• 75: Ironwood Pharmaceuticals Inc. – Key customers
• 76: Ironwood Pharmaceuticals Inc. – Segment focus
• 77: Mallinckrodt Plc – Overview
• 78: Mallinckrodt Plc – Business segments
• 79: Mallinckrodt Plc – Key offerings
• 80: Mallinckrodt Plc – Key customers
• 81: Mallinckrodt Plc – Segment focus
• 82: Merck & Co. Inc. – Overview
• 83: Merck & Co. Inc. – Business segments
• 84: Merck & Co. Inc. – Key offerings
• 85: Merck & Co. Inc. – Key customers
• 86: Merck & Co. Inc. – Segment focus
• 87: Novartis AG – Overview
• 88: Novartis AG – Business segments
• 89: Novartis AG – Key offerings
• 90: Novartis AG – Key customers
• 91: Novartis AG – Segment focus
• 92: Pfizer Inc. – Overview
• 93: Pfizer Inc. – Business segments
• 94: Pfizer Inc. – Key offerings
• 95: Pfizer Inc. – Key customers
• 96: Pfizer Inc. – Segment focus
• 97: SHIONOGI Co. Ltd. – Overview
• 98: SHIONOGI Co. Ltd. – Business segments
• 99: SHIONOGI Co. Ltd. – Key offerings
• 100: SHIONOGI Co. Ltd. – Key customers
• 101: SHIONOGI Co. Ltd. – Segment focus
• 102: Takeda Pharmaceutical Co. Ltd. – Overview
• 103: Takeda Pharmaceutical Co. Ltd. – Product and service
• 104: Takeda Pharmaceutical Co. Ltd. – Key offerings
• 105: Takeda Pharmaceutical Co. Ltd. – Key customers
• 106: Takeda Pharmaceutical Co. Ltd. – Segment focus
• 107: Currency conversion rates for US$
• 108: Research Methodology
• 109: Validation techniques employed for market sizing
• 110: Information sources
• 111: List of abbreviations
【掲載企業】
AstraZeneca Plc, Bausch Health Companies Inc., Daiichi Sankyo Co. Ltd., Ironwood Pharmaceuticals Inc., Mallinckrodt Plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., SHIONOGI Co. Ltd., Takeda Pharmaceutical Co. Ltd.
【免責事項】
https://www.marketreport.jp/reports-disclaimer